-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![IPCU 2024 featured](https://volition.com/wp-content/uploads/2024/03/IPCU-2024-featured-e1709724119254.jpg)
Physical isolation of tumor associated ctDNA fragments for novel prostate cancer liquid biopsy
- Share
- Tweet
- Share on Facebook
- Share
![IPCU 2024 thumbnail](https://volition.com/wp-content/uploads/2024/03/IPCU-2024-thumbnail-e1709724031783.jpg)
![IPCU 2024 thumbnail](https://volition.com/wp-content/uploads/2024/03/IPCU-2024-thumbnail-e1709724031783.jpg)
Presentation titled: Physical isolation of tumor associated ctDNA fragments for novel prostate cancer liquid biopsy
Presented at: 34th International Prostate Cancer Update
Pamart et al
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields